Key2Brain AB develops a brain-targeting platform that utilizes targeted delivery mechanisms to enhance the efficacy of therapeutics for neurological disorders. This technology aims to improve drug penetration into the central nervous system, addressing the challenge of inadequate treatment effectiveness in brain-related conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Many biopharmaceutical drugs struggle to effectively cross the blood-brain barrier, limiting their therapeutic impact on central nervous system (CNS) disorders. This challenge hinders the development of treatments for neurological diseases that require precise drug delivery to the brain.
Solution
Key2Brain is developing a brain-targeting platform that utilizes single-domain antibodies to enhance the delivery of biopharmaceuticals across the blood-brain barrier. Their technology aims to improve the brain uptake of biologics and diagnostics, facilitating the preclinical development of therapeutics for CNS diseases. By enabling more efficient drug penetration into the brain, Key2Brain seeks to improve treatment and diagnostic options for a range of neurological conditions. The platform offers a solution for enhanced brain access, addressing a critical need in CNS drug development.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing biologics and diagnostics for central nervous system disorders.
Features
- Proprietary technology based on single-domain antibodies for targeted drug delivery to the brain.
- Enhanced brain uptake of biopharmaceuticals and diagnostics.
- Preclinical expertise to facilitate the development of CNS therapeutics.
- Collaboration and partnership model with academia and industry.